NASDAQ$GEHC
GE HealthCare Technologies Inc · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
GE HealthCare reported strong revenue growth driven by robust end market demand, improved pricing, and easing supply chain pressures.
GE HealthCare reported an 8% increase in revenues, reaching $4.9 billion, and a net income of $554 million for Q4 2022. The company's performance was driven by growth in Imaging, Patient Care Solutions (PCS), and Ultrasound, with a book-to-bill ratio of 1.07. GE HealthCare reaffirmed its 2023 guidance and introduced 2023 Adjusted EPS guidance.
- Revenues increased by 8% year-over-year, with organic revenues up by 13%.
- Net income was $554 million, compared to $564 million in the prior year.
- EPS was $1.21, while Adjusted EPS was $1.31.
- Cash flow from operating activities was $1.1 billion, and Free cash flow was $987 million.
Headline financials
Revenue & EPS history
GE HealthCare · Revenue · Quarterly
$4.94B
Revenue by segment
GE HealthCare · $3.97B total across 4 segments · Q4 2022
- Imaging$2.7B—68.0%
- Patient Care$786M—19.8%
- Pharma Diagnostics$473M—11.9%
- Other$14M—0.4%
Forward guidance
The Company reaffirmed its guidance for full year 2023 and introduced Adjusted EPS guidance as follows:
Tailwinds
- Organic revenue growth in the range of 5% to 7% year-over-year.
- Adjusted EBIT margin in the range of 15.0% to 15.5%, reflecting an expansion of 50 to 100 basis points versus 2022 Standalone Adjusted EBIT margin of 14.5%.
- Adjusted effective tax rate (ETR) in the range of 23% to 25%.
- Adjusted EPS in the range of $3.60 to $3.75. This compares to 2022 Standalone Adjusted EPS of $3.38.
- Free cash flow conversion of 85% or more for the full year.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 15 quarterly earnings reports
-0.2%
Avg return
Earnings day
+0.2%
Avg return
5 days after
-0.3%
Avg return
30 days after
50%
8 / 16 earnings
Positive
+11.5%
Q4 2021
Best reaction
-12.9%
Q1 2026
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -12.9% | -10.9% | -8.9% | |
| Q4 2025 | +6.4% | +0.4% | -5.7% | |
| Q3 2025 | -2.7% | -6.2% | +0.7% | |
| Q1 2025 | +3.3% | +1.9% | +3.6% | |
| Q4 2024 | +8.8% | +7.9% | -4.6% | |
| Q3 2024 | +2.4% | +2.0% | -2.4% | |
| Q2 2024 | +0.9% | -1.4% | +2.6% | |
| Q1 2024 | -12.0% | -10.6% | -11.7% | |
| Q4 2021 | +11.5% | +10.8% | +26.2% | |
| Q3 2023 | +8.1% | +13.3% | +8.4% | |
| Q3 2022 | +8.1% | +13.3% | +8.4% | |
| Q2 2023 | -4.0% | -3.4% | -15.1% | |
| Q1 2023 | -8.7% | -7.3% | -9.0% | |
| Q1 2022 | -8.7% | -7.3% | -9.0% | |
| Q2 2022 | -2.3% | +0.8% | +4.4% | |
| Q4 2022 | -0.8% | +0.7% | +7.4% | |
| Q3 2021 | — | — | — | |
| Q2 2021 | — | — | — | |
| Q1 2021 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro